XML 29 R15.htm IDEA: XBRL DOCUMENT

Inventory

9 Months Ended

Sep. 30, 2021

6. Inventory

Our inventory balance consists of the following (in thousands):


	September 30,		December 31,
	2021		2020
Raw materials	$	1,275	$	1,275
Work-in-process		35,988		21,242
Finished goods		14,925		13,456
		52,188		35,973
Inventories-current		21,303		16,425
Inventories-noncurrent	$	30,885	$	19,548

Inventories, stated at the lower of cost and net realizable value, consist of raw materials, work in process and finished goods. At September 30, 2021, $21.3 million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At September 30, 2021, $30.9 million of inventory was classified as noncurrent on the condensed consolidated balance sheets as we did not expect this inventory to be consumed for commercial use within the next twelve months. We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.

We capitalize inventory after FDA approval as the related costs are expected to be recoverable through the commercialization of the product. Costs incurred prior to FDA approval are recorded as research and development expense in our statements of operations. At September 30, 2021, inventory with approximately $72.1 million of product costs incurred prior to FDA approval had not yet been sold. We expect to sell the pre commercialization inventory over the next 3 to 36 months and as a result, cost of product revenues for will reflect a lower average per unit cost of materials.